Compare Regeneron Pharmaceuticals Inc (REGN) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B), while YieldMax Universe Fund of Option Income ETFs trades at $7.49 (market cap $369.61M). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 206.7× YieldMax Universe Fund of Option Income ETFs's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while YieldMax Universe Fund of Option Income ETFs pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and YieldMax Universe Fund of Option Income ETFs for 55 Days on average.
| REGN | YMAX | |
|---|---|---|
Market Cap | $76.40B | $369.61M |
Volume | 626,381 | 659,132 |
Sector | Health | Income / Options Overlay |
52-Week High | $852.03 | $12.98 |
52-Week Low | $557.73 | $7.27 |
Typical Hold Time | 107 Days | 55 Days |
Enterprise Value | $71.12B | — |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
YMAX trades at $7.53, down 1.83% on the day, with a bearish technical signal driven by moving averages. The ETF maintains a high distribution yield with weekly dividends, though recent coverage highlights concerns about NAV erosion and sustainability. Technical indicators show mixed signals with RSI neutral but ADX suggesting selling pressure, while support levels cluster around $7-8.
The outlook remains cautious due to structural concerns about distribution sustainability and NAV performance. While the high yield attracts income investors, the fund faces risks from its fee structure and portfolio strategy. Analyst sentiment appears mixed with some highlighting yield benefits while others warn of principal erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
